These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 11774975)
1. GI events leading to death in association with celecoxib and rofecoxib. Weaver J; Bonnel RA; Karwoski CB; Brinker AD; Beitz J Am J Gastroenterol; 2001 Dec; 96(12):3449-50. PubMed ID: 11774975 [No Abstract] [Full Text] [Related]
2. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Maetzel A; Krahn M; Naglie G Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781 [TBL] [Abstract][Full Text] [Related]
3. A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data. Kasliwal R; Layton D; Harris S; Wilton L; Shakir SA Drug Saf; 2005; 28(9):803-16. PubMed ID: 16119973 [TBL] [Abstract][Full Text] [Related]
4. [COX-2 inhibitors--one step forward and two steps back]. Evensen S; Spigset O; Slørdal L Tidsskr Nor Laegeforen; 2005 Apr; 125(7):875-8. PubMed ID: 15815733 [TBL] [Abstract][Full Text] [Related]
6. Rofecoxib, Merck, and the FDA. Wolfe MM N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625749 [No Abstract] [Full Text] [Related]
7. Adverse Drug Events Involving COX-2 Inhibitors. Verrico MM; Weber RJ; McKaveney TP; Ansani NT; Towers AL Ann Pharmacother; 2003 Sep; 37(9):1203-13. PubMed ID: 12921500 [TBL] [Abstract][Full Text] [Related]
8. Are selective COX 2 inhibitors superior to traditional NSAIDs? Rofecoxib did not provide unequivocal benefit over traditional NSAIDs. Budenholzer BR BMJ; 2002 Jul; 325(7356):161; author reply 161. PubMed ID: 12130617 [No Abstract] [Full Text] [Related]
14. [Safety of celecoxib and rofecoxib: a critical overview]. Alegre Del Rey EJ Med Clin (Barc); 2002 Feb; 118(6):237. PubMed ID: 11864549 [No Abstract] [Full Text] [Related]
15. [Tubulointerstitial nephritis associated with treatment with selective Cox-2 inhibitors, celecoxib and rofecoxib]. Ortiz M; Mon C; Fernández MJ; Sánchez R; Mampaso F; Alvarez Ude F Nefrologia; 2005; 25(1):39-43. PubMed ID: 15789535 [TBL] [Abstract][Full Text] [Related]
16. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Johnsen SP; Larsson H; Tarone RE; McLaughlin JK; Nørgård B; Friis S; Sørensen HT Arch Intern Med; 2005 May; 165(9):978-84. PubMed ID: 15883235 [TBL] [Abstract][Full Text] [Related]
17. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Laine L; Connors LG; Reicin A; Hawkey CJ; Burgos-Vargas R; Schnitzer TJ; Yu Q; Bombardier C Gastroenterology; 2003 Feb; 124(2):288-92. PubMed ID: 12557133 [TBL] [Abstract][Full Text] [Related]
18. The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. Strand V; Hochberg MC Arthritis Rheum; 2002 Aug; 47(4):349-55. PubMed ID: 12209478 [No Abstract] [Full Text] [Related]
19. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice. Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789 [TBL] [Abstract][Full Text] [Related]
20. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors. Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]